patient treated at Emory University Hospital and the second patient treated at University of Michigan Health System. The multicenter trial is designed to treat up to 15 ambulatory ALS patients in five different dosing cohorts. Patients in the first cohort received 10 injections of 200,000 cells per injection. In subsequent cohorts, the dose will increase in both number of injections and cells per injection, advancing up to a maximum of 40 injections and up to 400,000 cells per injection in the fifth cohort. The first 12 patients will receive injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function. The final three patients will receive both cervical and lumbar injections.
This quarter, Neuralstem increased its global IP portfolio to 49 issued and 59 pending patents. The company received issuance of Japan Patent # 5266297, and filed a new patent application in South Korea, 10-2013-7020263, both related to the company's existing stem cell technology. The company also filed a new U.S. patent application 61/844,165, which covers methods of treating cognitive defects with spinal cord neural stem cells.
In September, the company raised aggregate gross proceeds of $4,556,000 in a registered direct offering.
In September, President and CEO Richard Garr presented at the Stem Cells & Regenerative Medicine Congress. NSI-566/ALS Phase I patient, Ted Harada, also spoke about his experience with ALS and treatments at the congress.
In October, University of Michigan Health System, the second center for the NSI-566/ALS Phase II dose escalation trial, treated its second patient. With one patient already treated at Emory University Hospital, this represented the completion of the first of the trial's five cohorts in less than a month's time.
In October, Dr. Eva Feldman, MD, PhD, gave an update on the NSI-566/ALS trial at the annual AmePage: 1 2 3 4 5 6 7 8 9 Related biology technology :1
. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta2
. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase3
. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 20124
. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering5
. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial6
. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London7
. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions8
. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference9
. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports10
. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update11
. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update